As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.
19 Analysts have issued a Aeglea BioTherapeutics Inc forecast:
19 Analysts have issued a Aeglea BioTherapeutics Inc forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | - - |
-
|
|
| EBIT (Operating Income) EBIT | -224 -224 |
15%
15%
|
|
| Net Profit | -149 -149 |
31%
31%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.
| Head office | United States |
| CEO | Cameron Turtle |
| Employees | 65 |
| Founded | 2013 |
| Website | spyre.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


